Get to know our clinical trials
Phase III clinical trial to evaluate RLY-2608 fulvestrant compared to capivasertib fulvestrant as a treatment for locally advanced or metastatic breast cancer.
THE PRIMARY OBJECTIVE IS TO COMPARE THE EFFICACY OF RLY-2608 FULVESTRANT RELATIVE TO CAPIVASERTIB FULVESTRANT BY EVALUATING PFS IN THE OVERALL POPULATION AND IN THE KINASE POPULATION USING BICR.
Technical Summary
- PHASE III RANDOMIZED OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RLY-2608 FULVESTRANT COMPARED TO CAPIVASERTIB FULVESTRANT AS A TREATMENT FOR LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH A PIK3CA MUTATION, HORMONE RECEPTOR-POSITIVE, AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HRﱱ) FOLLOWING RECURRENCE OR PROGRESSION DURING OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR
- Code EudraCT: 2025-520785-22-00
- Protocol number: RLY-2608-102
- Promoter: Relay Therapeutics, Inc.
- Molecule/Drug: RLY-2608 Fulvestrant
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.